公开(公告)号：EP1852130B1

公开(公告)日：2012-06-20

申请号：EP06714571.4

申请日：2006-02-24

申请人： HISAMITSU PHARMACEUTICAL CO., INC.

发明人： KOZUMA, Miyuki ,  TANAKA, Koji ,  HASHIMOTO, Yoshiaki ,  SUZUKI, Shigeo

IPC分类号： A61K47/24 ,  A61K9/70 ,  A61K31/192 ,  A61P29/00

CPC分类号： A61K31/192 ,  A61K9/0014

摘要： Disclosed is a medicine for external application which contains an anti-inflammatory agent, an organic ultraviolet absorbent and soy lecithin. This medicine for external application enables to surely prevent photo-allergies caused by a transdermal preparation containing a photosensitive anti-inflammatory agent.

公开(公告)号：EP2457592A1

公开(公告)日：2012-05-30

申请号：EP10802225.2

申请日：2010-07-15

申请人： Hisamitsu Pharmaceutical Co., Inc. ,  Toppan Printing Co., Ltd.

发明人： TERAHARA Takaaki ,  TOKUMOTO Seiji ,  TAMURA Akira ,  YAMADA Yumiko

IPC分类号： A61K47/34 ,  A61K9/70 ,  A61M37/00

CPC分类号： A61K9/0021 ,  A61B5/150022 ,  A61B5/150282 ,  A61B5/150427 ,  A61B5/150511 ,  A61B5/150969 ,  A61B5/150984 ,  A61K47/34 ,  A61M37/0015 ,  A61M2037/0023 ,  A61M2037/0046 ,  A61M2037/0053

摘要： Relations between crystallinity and performance of a biodegradable resin, between weight-average molecular weight and strength thereof, and between weight-average molecular weight and performance thereof were clarified. As a result thereof, when a microneedle array was provided with microneedles containing noncrystalline polylactic acid which had a weight-average molecular weight of 40,000 to 100,000, it was possible to obtain a microneedle array which could maintain its functional performance.

摘要翻译： 澄清了可生物降解树脂的结晶度和性能之间的关系，其重均分子量和强度之间以及重均分子量和性能之间的关系。 作为其结果，当微针阵列设置有包含重均分子量为40,000至100,000的非结晶性聚乳酸的微针时，可以获得可保持其功能性能的微针阵列。

公开(公告)号：EP1806151B1

公开(公告)日：2012-05-23

申请号：EP05806192.0

申请日：2005-11-09

申请人： HISAMITSU PHARMACEUTICAL CO., INC.

发明人： WAKAMATSU, Masato ,  SAEKI, Masakazu, HISAMITSU PHARMA. CO., INC. ,  YOSHINAGA, Takaaki, HISAMITSU PHARMA. CO., INC.

IPC分类号： A61K47/18 ,  A61K9/70 ,  A61K31/192 ,  A61K31/196 ,  A61K31/381 ,  A61K31/405 ,  A61K31/42 ,  A61K31/5415 ,  A61K31/63 ,  A61K45/00 ,  A61K47/02 ,  A61K47/14 ,  A61K47/32 ,  A61K47/34

CPC分类号： A61K45/06 ,  A61K9/7053 ,  A61K31/192 ,  A61K31/196 ,  A61K31/381 ,  A61K31/405 ,  A61K31/42 ,  A61K31/5415 ,  A61K33/08 ,  A61K47/183 ,  A61K2300/00

摘要： Disclosed is a drug for external use characterized by containing a medicinal component such as an anti-inflammatory drug and an edetate, while substantially containing no water.

公开(公告)号：EP2327419A1

公开(公告)日：2011-06-01

申请号：EP09773249.9

申请日：2009-05-22

申请人： Hisamitsu Pharmaceutical Co., Inc. ,  Juridical Foundation The Chemo-Sero-Therapeutic Research Institute

发明人： NOZAKI Chikateru ,  KAMINAKA Kazuyoshi ,  MATSUDA Junichi ,  TERAHARA Takaaki ,  KUWAHARA Tetsuji ,  TOKUMOTO Seiji

IPC分类号： A61K39/145 ,  A61K9/00 ,  A61K9/70 ,  A61K39/00 ,  A61K39/39 ,  A61K47/10 ,  A61K47/34 ,  A61K47/36 ,  A61L31/00 ,  A61M37/00 ,  A61P31/16

摘要： The present invention provides a method for enhancing the immunogenicity using a microneedle device capable of enhancing the immunogenicity of an influenza vaccine. According to the method for enhancing the immunogenicity using the present microneedle device, a microneedle device having microneedles made of polylactic acid, coated with an influenza vaccine composed of an antigen having type A strain (H1N1), type A strain (H3N2), and type B strain as active ingredients is brought into direct contact with the skin so as to transcutaneously administer the aforementioned influenza vaccine. After the transcutaneous administration, lauryl alcohol is applied to the site of the skin where the microneedle device has been brought into direct contact.

摘要翻译： 本发明提供了用于使用能够增强流感疫苗的免疫原性的微针装置增强的免疫原性的方法。 。根据该方法用于增强使用本微针装置的免疫原性，具有微针的微针装置由聚乳酸的，在具有A型株（H1N1）抗原组成的流感疫苗涂覆有A型株（H3N2），和类型 B株作为活性成分被带入与皮肤直接接触，以便经皮施用上述的流感疫苗。 经皮给药后，月桂醇被应用到微针系统已经直接接触皮肤的部位。

公开(公告)号：EP2286814A1

公开(公告)日：2011-02-23

申请号：EP09746617.1

申请日：2009-05-13

申请人： Hisamitsu Pharmaceutical Co., Inc.

发明人： YASUKOCHI Takashi ,  NAKA Yukihisa ,  ENDO Tsuyoshi ,  ADACHI Hirotoshi

IPC分类号： A61K31/439 ,  A61K9/70 ,  A61K47/10 ,  A61K47/32

CPC分类号： A61K31/473 ,  A61K9/7053 ,  A61K9/7061 ,  A61K9/7076

摘要： The percutaneous absorption preparation comprises a support and a drug-containing pressure-sensitive adhesive layer formed on at least one side of the support, wherein the drug-containing pressure-sensitive adhesive layer comprises, as essential constituent components, an adhesive base, palonosetron or a pharmaceutically acceptable acid addition salt thereof, and at least one type of fatty alcohol selected from the group consisting of C6-12 straight-chain saturated alcohols, C10-22 straight-chain unsaturated alcohols, C 10-22 branched alcohols and C10-15 cyclic alcohols, and the constituent components other than palonosetron or its pharmaceutically acceptable acid addition salt are carboxyl group-free components.

摘要翻译： 透皮吸收制剂包含载体和形成在载体的至少一侧上的含药物压敏粘合剂层，其中含药物压敏粘合剂层包含作为基本组成成分的粘合剂基质，帕洛诺司琼或 其药学上可接受的酸加成盐和至少一种选自C6-12直链饱和醇，C10-22直链不饱和醇，C10-22支链醇和C10-15直链饱和醇的脂肪醇 环状醇，除帕洛诺司琼或其药学上可接受的酸加成盐以外的构成成分为不含羧基的成分。

公开(公告)号：EP0993829B1

公开(公告)日：2011-01-12

申请号：EP97946064.9

申请日：1997-11-28

申请人： Hisamitsu Pharmaceutical Co., Inc.

发明人： HIRANO, Munehiko, Hisamitsu Pharm. Co., Inc. ,  MAKI, Masayoshi, Hisamitsu Pharm. Co., Inc. ,  SUZUKI, Tatsuaki, Hisamitsu Pharm. Co., Inc.

IPC分类号： A61K9/70 ,  A61M37/00

CPC分类号： A61K9/7053 ,  A61K9/7076 ,  A61K9/7092 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/439 ,  A61K31/538

摘要： A device for percutaneous treatment by a serotonin receptor antagonist, comprising at least three layers including A) a drug-impermeable backing layer, B) a drug storage layer provided between the backing layer and a drug release layer and containing a serotonin receptor antagonist, and C) a drug release layer constituted of a pressure-sensitive adhesive layer capable of controlling the release of a drug.

公开(公告)号：EP2264462A1

公开(公告)日：2010-12-22

申请号：EP09718200.0

申请日：2009-02-27

申请人： Hisamitsu Pharmaceutical Co., Inc. ,  Chiba-Prefecture

发明人： NAKAGAWARA, Akira ,  TAKATORI, Atsushi

IPC分类号： G01N33/574 ,  C07K16/28 ,  G01N33/15 ,  G01N33/50 ,  A61K45/00 ,  A61P35/00 ,  C12N15/09 ,  C12Q1/02

CPC分类号： G01N33/574 ,  C07K16/18 ,  C07K16/2863 ,  G01N33/5011 ,  G01N2333/71 ,  G01N2500/00

摘要： A screening method for a therapeutic agent for cancer, the method including: a step of measuring an interaction between NLRR1 and EGFR under each condition of being in the presence of a test substance and in the absence of a test substance; and a step of determining that the test substance is a therapeutic agent for cancer when the interaction between NLRR1 and EGFR in the presence of the test substance is weaker than the interaction between NLRR1 and EGFR in the absence of the test substance.

摘要翻译： 一种癌症治疗剂的筛选方法，所述方法包括：在存在测试物质的情况下和在不存在测试物质的条件下测量NLRR1与EGFR之间相互作用的步骤; 在测试物质存在的情况下当NLRR1和EGFR之间的相互作用弱于NLRR1和EGFR之间的相互作用时，确定测试物质是癌症治疗剂的步骤。

公开(公告)号：EP1795597B1

公开(公告)日：2010-08-18

申请号：EP06017801.9

申请日：2002-05-30

申请人： Chiba-Prefecture ,  Hisamitsu Pharmaceutical Co., Inc.

发明人： Nakagawara, Akira

IPC分类号： C12N15/12 ,  C12Q1/68 ,  G01N33/50

CPC分类号： C07K14/47

公开(公告)号：EP2204177A1

公开(公告)日：2010-07-07

申请号：EP09177321.8

申请日：2009-11-27

申请人： Hisamitsu Pharmaceutical Co., Inc. ,  CHIBA PREFECTURE

发明人： Tatsumi, Yasutoshi ,  Nakagawara, Akira

IPC分类号： A61K31/713 ,  C12Q1/68 ,  C12N15/113

CPC分类号： G01N33/57434 ,  A61K31/7105 ,  A61K31/713 ,  C12Q1/6886 ,  C12Q2600/158 ,  C12Q2600/178 ,  G01N33/57407 ,  G01N33/57423 ,  G01N33/57442 ,  G01N33/57446 ,  G01N2333/4707

摘要： A novel cancer marker is provided. A method for detecting cancer using a level of BMCC1 gene expression as an indication is provided, in which the cancer is selected from the group consisting of prostate cancer, lung cancer, gastric cancer, bladder cancer, and uterine cancer.

摘要翻译： 提供了一种新的癌症标志物。 提供了使用BMCC1基因表达水平作为指标检测癌症的方法，其中癌症选自前列腺癌，肺癌，胃癌，膀胱癌和子宫癌。

公开(公告)号：EP1739186B1

公开(公告)日：2009-09-30

申请号：EP05727106.6

申请日：2005-03-23

申请人： Hisamitsu Pharmaceutical Co., Inc. ,  Chiba-Prefecture

发明人： NAKAGAWARA, Akira, Chiba Cancer Ctr Research Inst. ,  OZAKI, Toshifumi, Chiba Cancer Ctr Research Inst.

IPC分类号： C12Q1/02 ,  A61K38/00 ,  A61K48/00 ,  A61P35/00 ,  C12Q1/48 ,  G01N33/15 ,  G01N33/50 ,  C12N15/09

CPC分类号： G01N33/502 ,  A61K38/00 ,  C07K14/4747 ,  G01N33/5008 ,  G01N2510/00

摘要： A method of screening a compound capable of accelerating apoptosis, comprising the judging step of judging a compound capable of intensifying the interaction between p73 and IKK-alpha as a compound capable of accelerating apoptosis.